New Insights on Type 2 Diabetes Remission from Diabetes Canada Guidelines

Diabetes remission is a concept that has been gaining attention as new treatments and interventions become available in the Diabetes Canada Clinical Practice Guidelines. How do we define diabetes remission, and what strategies can we employ to sustain it once it has been attained?

Our host, endocrinologist Dr. Hertzel Gerstein, professor of medicine at McMaster University and Hamilton Health Sciences, takes a deeper look into this topic with Dr. Kaberi Dasgupta, a physician scientist and professor of medicine at McGill University and the McGill University Health Centre.

This episode explores the latest updates from the Diabetes Canada Clinical Practice Guidelines on remission of type 2 diabetes (T2D) and other new approaches in development.

In their discussion, they detail the definition of remission in diabetes and what it means for the patient, before explaining the importance of early intervention in T2D. Together, they review two approaches included in the Canadian clinical practice guidelines to achieving remission: bariatric surgery and low-energy diets. They also discuss the importance of sustaining weight loss by continuing to adhere to the same healthy diet and lifestyle modifications that were implemented to attain remission.

Ongoing research efforts focused on prevention, treatment, and remission of diabetes continue to emerge, with more discoveries expected in the future.

Don’t miss the conversation!

The views and opinions expressed in this episode are those of the speakers and do not necessarily reflect the views or positions of any entities they represent.

Declaration of conflict of interest:

Dr. Gerstein

• Membership on advisory board or speakers’ bureaus: Sanofi, Lilly, Merck, AstraZeneca, DKSH, Zuellig, Novo Nordisk, Abbott, Pfizer, Kowa, Hanmi, Carbon Brand, Jiangsu Hanson Pharma. Funded grants, research, or clinical trials: Eli Lilly, Merck, AstraZeneca, Novo Nordisk

Dr. Dasgupta:

• Funded grants, research, or clinical trials: CIHR, The Lawson Foundation, The JR McConnell Foundation.

MAT-CA-2300840